IP Library › Granted Patent US 8,114,398
Granted Patent B2
US 8,114,398 · App. 12/089,627 · Granted Feb 14, 2012

EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,398
App. No.
12/089,627
Granted
Feb 14, 2012
Kind
B2
Abstract

The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.

Claims (3)

1. An isolated Egl Nine homolog 2 (EGLN2) protein comprising the amino acid sequence of SEQ ID NO: 3.

2. A therapeutic composition comprising an EGLN2 protein comprising the amino acid sequence according to SEQ ID NO: 3 for the prevention or treatment of coronary heart diseases.

3. The therapeutic composition according to claim 2 , wherein the coronary heart disease is myocardial infarction.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2008
From: KOZIAN, DETLEF; HERRMANN, MATTHIAS
To: SANOFI-AVENTIS
Reel/Frame 021315/0714 →